BPC 157 and Healing Peptides: Hype or Hope? A Doctor's Comprehensive Perspective MSK Doctor Zaid Matti GLP 1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes Circulation Printed GLP 1 and the BPC 157 TB stack otherwise known as the 'Wolverine' peptide. Current Status of Glucagon like Peptide 1 Receptor Agonists in Metabolic Dysfunction associated Steatotic Liver Disease: A Clinical Perspective Key Findings: Duration Reduction: The study found that GLP 1 therapy significantly shortens the duration of BoNT A effects: In chronic migraine treatment, the mean duration dropped from 14.0 weeks to between 11.8 Benefits of GLP 1 (Glucagon Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists Stroke